Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

h and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015  Marc Tessier-Lavigne, president ... gift of $100 million from The Marie-Josée and ... new laboratory building that will be the centerpiece ... Marie-Josée and Henry R. Kravis Research Building, two ... Drive, spanning approximately three city blocks following the ...
(Date:5/20/2015)... May 20, 2015  Cypher Genomics, Inc., a ... with Celgene Corporation to apply Cypher,s Coral TM ... associate with patient response to innovative medicines. The ... help accelerate patient access to the right medicine ... research and development and potentially inform new companion ...
(Date:5/20/2015)... 19, 2015 Research and Markets ... the "Bone Morphogenetic Proteins Market (Types : ... and Oral - Maxillofacial) - Global Industry Analysis, ... 2022" report to their offering. ... based on the types of recombinant BMPs, applications, ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 Optivia ... assay services for Drug-Drug Interactions (DDI), Metabolism and ... a world leader in assessing impact of drugs ... Pharmacology supported by biosimulation, announced today that they ... allows both companies to expand their product and ...
Breaking Biology Technology:The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... Louvain, Belgium Cancer is the major cause of ... predict that, by about 2010, cancer will be the ... VIB scientists connected to the Katholieke Universiteit Leuven, in ... studying the anti-cancer action of anti-PLGF. This substance appears ...
... Delft University of Technologys Kavli Institute of Nanoscience and ... succeeded in controlling the spin of a single electron ... for a much simpler realization of the building blocks ... publish their work in Science Express on Thursday 1 ...
... BioFuel Energy Corp. (Nasdaq:,BIOF) announced today that ... Wednesday, November 7, 2007, after the market closes. ... plans to host a conference call on Thursday, ... discuss the third quarter results. To,participate, please dial ...
Cached Biology Technology:On the road to a new cancer therapy -- starving the tumor 2On the road to a new cancer therapy -- starving the tumor 3Delft University of Technology rotates electron spin with electric field 2
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... to play a major role in the studies ... a life-threatening parasitic disease that kills nearly one ... advanced our understanding of malaria, new models are ... Institute for Mathematical and Biological Synthesis (NIMBioS) is ...
... 18, 2011 -- Physicists and bioengineers have developed an ... a worm just by shining a tightly focused beam ... The pioneering optogenetic research, by a team at Harvard ... Massachusetts Medical School, is described this week in the ...
... the first view of DNA damage throughout the entire ... a valuable new insight into the development and treatment ... Dr Simon Reed and Dr Yumin Teng from Cardiff ... a unique way of measuring DNA damage frequency using ...
Cached Biology News:Malaria modeling and control focus of workshop 2Sharply focused on neurons, light controls a worm's behavior 2New technology provides first view of DNA damage within entire human genome 2
...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... MasterAmp™ Taq DNA Polymerase is a ... aquaticus. Having optimal activity at temperatures ... thermostable enzyme used for PCR and ... purpose. The enzyme has an intrinsic ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
Biology Products: